Prescribing report: Reviewing SABA treatment for asthma management in adolescents and adults

0 comments

save

feedback

For more than 50 years, people with asthma have been prescribed a short-acting beta₂-agonist (SABA) as the first-line treatment for symptom relief. However, the accumulated weight of evidence has shifted and regular use of a SABA without concurrent inhaled corticosteroid (ICS) is no longer recommended for adolescents or adults.

Published: 4 August 2020

Click here if you are not a prescriber, to see the national report version.

Comment features

You can add replies to a comment. Simply click the "Reply to comment" button and complete the form. Your reply, once approved, will appear below the comment to which you replied (if there are multiple replies to a comment, they will appear in order of submission).

You can add a new comment by scrolling to the bottom of the discussion and clicking the "Add a comment" button.

If someone adds a reply to one of your comments (or replies) you will receive an email notifying you of this. You can opt out of (or into if currently out) all comment notification emails by clicking the button below.

There are currently no comments for this article.

Please login to make a comment.

CPD information

Prescribing Reports

Audits

CME Quizzes

Peer Group Discussions

My Bpac account

Prescribing report: Reviewing SABA treatment for asthma management in adolescents and adults

Comment features

Discussion

Partner links